Veracyte Raises $550M In Upsized Equity Offering For Decipher Biosciences Acquisition


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • Veracyte Inc (NASDAQ: VCYT) has priced an upsized underwritten public offering of around 7.4 million common shares at $74 per share, with gross proceeds of approximately $550 million. Earlier, the company announced the equity offering of $400 million.
  • The offer price represents a discount of around 5% from the last close price of $77.87 on Thursday.
  • Underwriters have an option to purchase up to an additional 1.1 million.
  • The offering is expected to close by February 9.
  • Goldman Sachs and SVB Leerink are acting as joint lead book-running managers for the offering.
  • The majority of the proceeds from the offering will be used to finance Decipher Biosciences acquisition.
  • Price Action: VCYT shares closed 5.5% higher at $77.87 on Thursday.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechM&ANewsOfferingsGeneral